A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection.

ABSTRACT: Acute allograft rejection remains common after liver transplantation despite modern immunosuppressive agents. In addition, the long-term side effects of these regimens, including opportunistic infections, are challenging. This study evaluated the safety and clinical feasibility of umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy in liver transplant patients with acute graft rejection. Twenty-seven liver allograft recipients with acute rejection were randomly assigned into the UC-MSC infusion group or the control group. Thirteen patients received one infusion of UC-MSCs (1 × 10⁶ /kg body weight); one patient received multiple UC-MSC infusions; 13 patients were used as controls. All enrolled patients received conventional immunosuppressive agents with follow-up for 12

SUBMITTER: Shi M 

PROVIDER: S-EPMC5702514 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature